South Korea’s Celltrion CEO to Be Probed in Stocks Trading Case
October 8, 2013 Leave a comment
South Korea’s Celltrion CEO to Be Probed in Stocks Trading Case
South Korea’s financial regulator plans to ask prosecutors to investigate the chief executive officer of Celltrion Inc. over alleged stock price manipulation, the drug manufacturer said today. The Financial Services Commission is asking prosecutors to probe the actions of Celltrion’s largest shareholder, the company said in an e-mailed statement. Celltrion disagrees with the FSC’s decision and plans to cooperate with prosecutors, the company said. Celltrion’s largest shareholder is CEO Seo Jung Jin, spokesman Kim Joon Seok confirmed by phone.The FSC earlier said that the CEO of a Kosdaq-listed company manipulated the company’s share price three times since 2011 for fundraising and to prevent stock declines, identifying the company only with the letter “C.”
The decision comes after South Korean President Park Geun Hye instructed her aides in March to prepare stricter measures against stock manipulation, prompting financial regulators to submit bills to parliament to intensify penalties and enable quicker investigation of suspected market manipulation activity.
Shares (068270) of Celltrion rose the most in a month in Seoul, closing 5.6 percent higher at 46,150 won and paring this year’s loss to 12 percent. The Kosdaq index, where Celltrion is listed, has advanced 6.6 percent during the same period. The FSC issued its statement after the close of trading.
Celltrion last month issued a statement denying using internal information to make a profit, without specifying whether the statement referred to the company or Seo.
Incheon-based Celltrion makes and sells biosimilar products and also manufactures medicine on a contract basis, according to the company’s website. The company in June won European backing to sell a copy of Johnson & Johnson’s Remicade, a $6 billion arthritis therapy.
Temasek Holdings Pte, Singapore’s state-owned investment company, is the second-biggest shareholder of Celltrion with a 14.9 percent holding as of June via its Ion Investments BV unit, according to a Celltrion regulatory filing on July 1.
To contact the reporters on this story: Seonjin Cha in Seoul at scha2@bloomberg.net; Sharon Cho in Seoul at ccho28@bloomberg.net